BioTime, Inc. (NYSEMKT:BTX) saw a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 6,767,992 shares, a decline of 0.9% from the October 13th total of 6,827,321 shares. Based on an average daily trading volume, of 417,019 shares, the short-interest ratio is presently 16.2 days. Approximately 5.7% of the shares of the stock are short sold.

In other news, Director Broadwood Partners, L.P. acquired 2,692,307 shares of the stock in a transaction that occurred on Friday, October 13th. The shares were bought at an average cost of $2.60 per share, for a total transaction of $6,999,998.20. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last quarter, insiders purchased 2,716,203 shares of company stock worth $7,061,218.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Family Management Corp lifted its stake in BioTime by 1.4% in the 2nd quarter. Family Management Corp now owns 140,371 shares of the biotechnology company’s stock worth $442,000 after purchasing an additional 2,000 shares in the last quarter. American International Group Inc. lifted its stake in BioTime by 8.3% in the 1st quarter. American International Group Inc. now owns 39,794 shares of the biotechnology company’s stock worth $137,000 after purchasing an additional 3,036 shares in the last quarter. Metropolitan Life Insurance Co. NY raised its position in shares of BioTime by 14.7% during the 1st quarter. Metropolitan Life Insurance Co. NY now owns 57,694 shares of the biotechnology company’s stock valued at $199,000 after buying an additional 7,411 shares during the period. Voya Investment Management LLC raised its position in shares of BioTime by 38.3% during the 2nd quarter. Voya Investment Management LLC now owns 32,496 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 8,996 shares during the period. Finally, Moors & Cabot Inc. raised its position in shares of BioTime by 25.2% during the 2nd quarter. Moors & Cabot Inc. now owns 49,630 shares of the biotechnology company’s stock valued at $154,000 after buying an additional 10,000 shares during the period.

BioTime (NYSEMKT BTX) traded down $0.13 on Monday, reaching $2.43. 326,397 shares of the company’s stock were exchanged, compared to its average volume of 429,683. BioTime has a twelve month low of $2.19 and a twelve month high of $3.96.

A number of research analysts have weighed in on BTX shares. Zacks Investment Research lowered shares of BioTime from a “hold” rating to a “sell” rating in a research note on Friday, October 20th. BidaskClub lowered shares of BioTime from a “sell” rating to a “strong sell” rating in a research note on Wednesday, October 18th. Three analysts have rated the stock with a sell rating and two have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $5.33.

TRADEMARK VIOLATION NOTICE: “BioTime, Inc. (BTX) Sees Significant Drop in Short Interest” was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at https://www.watchlistnews.com/biotime-inc-btx-sees-significant-drop-in-short-interest/1701226.html.

About BioTime

BioTime, Inc is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology.

Receive News & Ratings for BioTime Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.